Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.

Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, Avezum A, Probstfield JL, Dans T, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial Investigators.

Circulation. 2012 Dec 4;126(23):2705-12. doi: 10.1161/CIRCULATIONAHA.112.103234.

2.

The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.

Unger T.

Am J Cardiol. 2003 May 22;91(10A):28G-34G. Review.

PMID:
12781906
3.

Telmisartan prevents cardiovascular events in a broad group of at-risk patients.

Baumhäkel M, Böhm M.

Expert Opin Pharmacother. 2009 Dec;10(18):3113-7. doi: 10.1517/14656560903449231. Review.

PMID:
19925045
4.

Telmisartan for the management of patients at high cardiovascular risk.

Ruilope LM.

Curr Med Res Opin. 2011 Aug;27(8):1673-82. doi: 10.1185/03007995.2011.597378. Epub 2011 Jun 30. Review.

PMID:
21718097
5.

How cost-effective are new preventive strategies for cardiovascular disease?

Probstfield JL.

Am J Cardiol. 2003 May 22;91(10A):22G-27G. Review.

PMID:
12781905
6.

Clinical trial update: focus on the ONTARGET study.

Fitchett D.

Vasc Health Risk Manag. 2007;3(6):901-8. Review.

7.

Telmisartan in high-risk cardiovascular patients.

Weber MA.

Am J Cardiol. 2010 Jan 4;105(1 Suppl):36A-43A. doi: 10.1016/j.amjcard.2009.10.008. Review.

PMID:
20102972
8.

Telmisartan for the reduction of cardiovascular morbidity and mortality.

Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G.

Expert Rev Clin Pharmacol. 2011 Mar;4(2):151-61. doi: 10.1586/ecp.10.141. Review.

PMID:
22115399
9.

The Dietary Patterns Methods Project: synthesis of findings across cohorts and relevance to dietary guidance.

Liese AD, Krebs-Smith SM, Subar AF, George SM, Harmon BE, Neuhouser ML, Boushey CJ, Schap TE, Reedy J.

J Nutr. 2015 Mar;145(3):393-402. doi: 10.3945/jn.114.205336. Epub 2015 Jan 21. Review.

10.

Benefits of the Mediterranean Diet: Insights From the PREDIMED Study.

Martínez-González MA, Salas-Salvadó J, Estruch R, Corella D, Fitó M, Ros E; PREDIMED INVESTIGATORS.

Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):50-60. doi: 10.1016/j.pcad.2015.04.003. Epub 2015 May 1. Review.

PMID:
25940230
11.

Dietary patterns, Mediterranean diet, and cardiovascular disease.

Martinez-Gonzalez MA, Bes-Rastrollo M.

Curr Opin Lipidol. 2014 Feb;25(1):20-6. doi: 10.1097/MOL.0000000000000044. Review. Erratum in: Curr Opin Lipidol. 2014 Aug;25(4):326.

PMID:
24370845
12.

Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.

Working Group on the Summit on Combination Therapy for CVD, Yusuf S, Attaran A, Bosch J, Joseph P, Lonn E, McCready T, Mente A, Nieuwlaat R, Pais P, Rodgers A, Schwalm JD, Smith R, Teo K, Xavier D.

Eur Heart J. 2014 Feb;35(6):353-64. doi: 10.1093/eurheartj/eht407. Epub 2013 Nov 27. Review.

PMID:
24288261
13.

Future of polypill use for the prevention of cardiovascular disease and strokes.

Chrysant SG, Chrysant GS.

Am J Cardiol. 2014 Aug 15;114(4):641-5. doi: 10.1016/j.amjcard.2014.05.049. Epub 2014 Jun 6. Review.

PMID:
24996555
14.

The Mediterranean and other Dietary Patterns in Secondary Cardiovascular Disease Prevention: A Review.

Panagiotakos DB, Notara V, Kouvari M, Pitsavos C.

Curr Vasc Pharmacol. 2016;14(5):442-451. Review.

PMID:
27456104
15.

Primary and secondary prevention of cardiovascular disease: is there a place for Internet-based interventions?

Pietrzak E, Cotea C, Pullman S.

J Cardiopulm Rehabil Prev. 2014 Sep-Oct;34(5):303-17. doi: 10.1097/HCR.0000000000000063. Review.

PMID:
25079147
16.

A polypill strategy to improve global secondary cardiovascular prevention: from concept to reality.

Castellano JM, Sanz G, Fernandez Ortiz A, Garrido E, Bansilal S, Fuster V.

J Am Coll Cardiol. 2014 Aug 12;64(6):613-21. doi: 10.1016/j.jacc.2014.06.009. Review. Erratum in: J Am Coll Cardiol. 2014 Oct 7;64(14):1539.

17.

Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.

Packard KA, Hilleman DE.

Cardiovasc Ther. 2016 Dec;34(6):415-422. doi: 10.1111/1755-5922.12211. Review.

PMID:
27473898
18.

The cardiovascular polypill: clinical data and ongoing studies.

Castellano JM, Bueno H, Fuster V.

Int J Cardiol. 2015 Dec;201 Suppl 1:S8-14. doi: 10.1016/S0167-5273(15)31027-5. Review.

19.

Global burden of CVD: focus on secondary prevention of cardiovascular disease.

Bansilal S, Castellano JM, Fuster V.

Int J Cardiol. 2015 Dec;201 Suppl 1:S1-7. doi: 10.1016/S0167-5273(15)31026-3. Review.

20.

THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW.

Grodzinsky A, Arnold SV, Jacob D, Draznin B, Kosiborod M.

Endocr Pract. 2017 Mar;23(3):363-371. doi: 10.4158/EP161309.RA. Epub 2016 Dec 14. Review.

PMID:
27967225

Supplemental Content

Support Center